What's Happening?
Aclipse Therapeutics has announced a collaboration with Mayo Clinic for the Phase 2 clinical development of M107, a novel drug candidate for treating gastroparesis. M107 aims to modify the disease by shifting pro-inflammatory M1 macrophages to M2 anti-inflammatory
macrophages, addressing the biological cause of gastroparesis. The Phase 2 study, known as the LOGAST trial, will begin enrollment in Q1 2026 and involve clinical investigators at Mayo Clinic campuses in Rochester, Phoenix, and Jacksonville. The collaboration leverages the expertise of both organizations to target macrophage-related inflammation in gastroparesis.
Why It's Important?
Gastroparesis is a chronic condition affecting stomach nerves and muscles, leading to stomach paralysis and delayed emptying. Current treatments are limited, and M107 represents a potential breakthrough as the first disease-modifying drug for gastroparesis. The collaboration with Mayo Clinic could accelerate the development and availability of this treatment, offering hope to patients suffering from this debilitating condition. Successful development of M107 could significantly impact the management of gastroparesis, improving patient outcomes and quality of life.
